Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$0.11.

  • Sangamo Therapeutics' EPS (Basic) fell 32000.0% to -$0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.45, marking a year-over-year increase of 3918.92%. This contributed to the annual value of -$0.49 for FY2024, which is 6714.65% up from last year.
  • Latest data reveals that Sangamo Therapeutics reported EPS (Basic) of -$0.11 as of Q3 2025, which was down 32000.0% from -$0.08 recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' EPS (Basic) registered a high of $0.13 during Q1 2023, and its lowest value of -$0.66 during Q2 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.29 (2022), whereas its average is -$0.25.
  • In the last 5 years, Sangamo Therapeutics' EPS (Basic) plummeted by 320000.0% in 2021 and then surged by 14333.33% in 2023.
  • Sangamo Therapeutics' EPS (Basic) (Quarter) stood at -$0.25 in 2021, then tumbled by 34.62% to -$0.34 in 2022, then fell by 2.7% to -$0.35 in 2023, then soared by 66.44% to -$0.12 in 2024, then increased by 5.17% to -$0.11 in 2025.
  • Its EPS (Basic) was -$0.11 in Q3 2025, compared to -$0.08 in Q2 2025 and -$0.14 in Q1 2025.